Renal cell carcinoma exome-derived, V(D)J recombination reads had an elevated presence and variability, for both TcR-α and -β, when compared to marginal tissue, reflecting an opportunity to assess tumor immunogenicity by comparison with marginal tissue T cells. PD-1, PD-L2, CTLA4 and FOXP3, all of which are implicated in the evasion of an anti-tumor immune response, had a significantly higher expression for samples representing co-detection of productive TcR-α and -β recombination reads. Samples representing tumors with productive TcR-α recombination reads but no detectable, productive TcR-β recombination reads, reflected a 20% survival advantage, and RNASeq data indicated an intermediate level of immune checkpoint gene expression for those...
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and has strong immu...
Renal carcinoma is the 20th most common cancer worldwide. Clear cell renal cell carcinoma is the mos...
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in ord...
The successful use of expanded tumor-infiltrating lymphocytes (TIL) in adoptive TIL therapies has be...
Tumor immunoscoring is rapidly becoming a universal parameter of prognosis, and T-cells isolated fro...
Immune cells within the tumor microenvironment (TME) play a critical role in regulating tumor develo...
Antigen recognition and T-cell mediated cytotoxicity are major tenets of cancer immunology that are ...
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (11...
Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinom...
Abstract Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cel...
Due to the highly immunogenic nature of renal cell carcinoma (RCC), the tumor microenvironment (TME)...
International audienceClear cell renal cell carcinoma (ccRCC) constitutes the most common renal cell...
BACKGROUND: Immunogenomics approaches to the characterization of renal cell carcinoma (RCC) have hel...
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in ord...
T-cell receptor sequencing (TCRseq) enables tracking of T-cell clonotypes recognizing the same antig...
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and has strong immu...
Renal carcinoma is the 20th most common cancer worldwide. Clear cell renal cell carcinoma is the mos...
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in ord...
The successful use of expanded tumor-infiltrating lymphocytes (TIL) in adoptive TIL therapies has be...
Tumor immunoscoring is rapidly becoming a universal parameter of prognosis, and T-cells isolated fro...
Immune cells within the tumor microenvironment (TME) play a critical role in regulating tumor develo...
Antigen recognition and T-cell mediated cytotoxicity are major tenets of cancer immunology that are ...
ADAPTeR is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (11...
Purpose Checkpoint therapy is now the cornerstone of treatment for patients with renal cell carcinom...
Abstract Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cel...
Due to the highly immunogenic nature of renal cell carcinoma (RCC), the tumor microenvironment (TME)...
International audienceClear cell renal cell carcinoma (ccRCC) constitutes the most common renal cell...
BACKGROUND: Immunogenomics approaches to the characterization of renal cell carcinoma (RCC) have hel...
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in ord...
T-cell receptor sequencing (TCRseq) enables tracking of T-cell clonotypes recognizing the same antig...
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and has strong immu...
Renal carcinoma is the 20th most common cancer worldwide. Clear cell renal cell carcinoma is the mos...
Checkpoint inhibitors target the inhibitory receptors expressed by tumor-infiltrating T cells in ord...